查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439672

泌尿系结石管理设备-全球市场回顾、竞争格局、市场预测（2030年）

Urolithiasis Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2023年，全球泌尿系结石管理设备市场规模将达到15.3108亿美元，到2030年将达到19.6312亿美元，2024-2030年预测期间复合年增长率为4.27%，预计将增长。 由于尿路结石或肾结石盛行率的上升，市场呈现出正面的成长。 此外，肥胖等久坐的生活方式是肾结石形成的危险因素，产品设计的创新、终末期肾病的风险增加、老年人口的增加以及对治疗方案的认识提高预计将在 2024 年至 2030 年间增加.在预测期内为市场成长做出贡献。

泌尿道结石治疗设备的市场动态

由于各种原因，泌尿结石管理设备市场的产品需求正在增加。 关键因素包括全世界尿路结石盛行率的增加。

根据欧洲泌尿外科协会（2019）的数据，尿路结石的盛行率从 1% 到 20% 不等，在加拿大、瑞典、美国等生活水准较高的国家，盛行率肾结石的发生率相当高（超过10%）。

根据英国泌尿科医师协会（2022 年）的数据，肾结石很常见。 接受CT扫瞄的患者有8%的几率患有肾结石，并且自20世纪初以来发病率一直在稳步上升。 此外，十分之一（9%）的人在一生中会患上结石。 男性比女性稍微更容易受到影响。 所有年龄层的患者都可能出现结石，但首次出现结石的高峰年龄是约 45 岁。

根据美国国家肾臟基金会 (2022) 的数据，每年有超过 50 万人因肾结石问题前往急诊室就诊。

此外，久坐的生活方式增加，例如过量饮酒和减少液体摄取量，也可能导致肾结石的形成。 此外，由于不良饮食习惯和缺乏运动等久坐生活方式，肥胖是形成肾结石的高风险因素，其负担的增加也可能促进泌尿结石管理设备市场的成长。是一种性别。

根据世界卫生组织（WHO）2022年数据，2016年全球肥胖人数约6.5亿。 各种研究也表明，肥胖者会产生更多的尿酸和草酸钙结石。

此外，老年人更容易形成肾结石，增加末期肾病的风险。 根据《2019年世界人口展望》，2019年全球65岁以上人口有7.03亿人。 因此，随着老年人口的增加，尿路结石盛行率增加，从而推高对尿路结石治疗设备的需求，进而推动全球尿路结石治疗设备市场的成长。

然而，输尿管镜设备的高成本以及内出血失血等术后併发症等某些因素可能会对泌尿系结石治疗设备市场的成长产生一定的限制。

COVID-19 大流行的爆发导致急诊就诊人数大幅减少。 此外，门诊预约被推迟，虚拟和电话咨询的需求增加。 这些变化导致由于医院床位、麻醉和治疗能力以及医务人员短缺而造成治疗的严重延误，对全球泌尿道结石管理设备市场产生了负面影响。

泌尿道结石治疗设备市场区隔分析

在泌尿道结石治疗设备市场的治疗领域，体外震波碎石机 (ESWL) 预计在预测期内（2024-2030 年）将占较高的市场占有率。 这可能是由于与这些设备相关的某些功能所造成的。

该产品领域的高市占率可归因于越来越多的患者采用这些设备和快速治疗。 ESWL 的主要优点是治疗完全非侵入性，因为结石治疗不涉及皮肤切口或使用侵入性手术器械。 相反，它使用衝击波将结石破碎成小块，并通过输尿管将其从膀胱排出。

本报告研究和分析了全球泌尿结石管理设备市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第1章泌尿道结石管理设备市场报告简介

第 2 章泌尿结石管理设备市场执行摘要

  • 调查范围
  • 市场概览
  • 竞争评估

第3章监理与专利分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章泌尿道结石治疗器材市场主要因素分析

  • 泌尿道结石管理设备市场驱动因素
    • 尿结石或肾结石的盛行率增加
    • 久坐的生活方式是形成肾结石的危险因子
    • 产品设计创新
    • 罹患末期肾病的风险增加
    • 老年人口增加
  • 泌尿道结石治疗设备市场的限制与挑战
    • 输尿管镜设备成本高
    • 术后併发症
  • 泌尿道结石管理设备的市场机会
    • 需要先进设备
    • 扩大抛弃式输尿管镜检查的机会

第5章波特对泌尿结石管理设备市场的五力分析

第6章COVID-19对泌尿结石治疗设备市场的影响分析

第7章泌尿道结石治疗器械市场布局

  • 依类型
    • 诊断
    • 治疗
  • 按最终用户
    • 医院
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第 8 章泌尿系结石管理设备市场：全球公司占有率分析 - 3 至 5 家主要公司

第9章泌尿结石治疗设备市场的公司与产品概况

  • Boston Scientific Corporation
  • EMS Urology
  • Advin Health Care
  • Inceler Medikal Co. Ltd.
  • Walz Elektronik GmbH
  • DirexGroup
  • Medispec Ltd.
  • Richard Wolf GmbH
  • STORZ MEDICAL AG
  • Olympus
  • General Electric Company (GE Healthcare)
  • ESAOTE SPA
  • Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
  • BK Medical Holding Company, Inc.
  • Hitachi Medical Systems
  • Laborie
  • DRAMINSKI S. A.
  • ACE Medical Devices Pvt. Ltd.
  • Siemens Healthcare Private Limited
  • Vimex Sp. z o.o.

第10章KOL观看次数

第 11 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

Product Code: DIMDCL0512

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of urolithiasis and sedentary lifestyle

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030. The Urolithiasis Management Devices market is witnessing positive growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market during the forecast period from 2024-2030.

Urolithiasis Management Devices Market Dynamics:

The Urolithiasis Management Devices market is witnessing a growth in product demand owing to various reasons. The key factor includes the rising prevalence of urolithiasis across the globe.

According to the European Association of Urology 2019, the prevalence rates for urinary stones vary from 1% to 20%, and in the countries with a high standard of life such as Canada, Sweden, or the US, renal stones prevalence is significantly high (>10%).

As per the British Association of Urological Surgeons 2022, Kidney stones are common. Patients undergoing a CT scan have an 8% chance of having kidney stones and its incidence has been steadily increasing since the early 20th century. Moreover, 1 in 11 people (9%) will get stone symptoms during their lifetime. Men are affected slightly more often than women. Patients of all ages suffer from stones, but the peak age for a first stone is around the age of 45.

According to the National Kidney Foundation 2022, over half a million people go to emergency rooms for kidney stone problems every year.

Moreover, a rise in sedentary lifestyle such as excessive consumption of alcohol, less consumption of water could also lead to the development of kidney stones. In addition, the growing burden of obesity among the population, a high-risk factor for the development of renal calculi, due to sedentary lifestyles such as poor dietary habits and lack of physical activities could also contribute to the Urolithiasis Management Devices market growth.

As per the World Health Organization (WHO) 2022 data, there was around 650 million obese population worldwide in the year 2016. Also, according to various studies, obese people develop more uric acid stones and calcium oxalate stones.

Also, the aging population is more prone to the formation of kidney stones and an increased risk of end-stage renal failure. As per the World Population Prospects, 2019, there were 703 million older persons aged 65 or over in 2019 globally. Therefore, as the aging population increases, there will be more prevalence of urolithiasis, which will eventually boost the demand for Urolithiasis Management Devices which will drive the growth of the Global Urolithiasis Management Devices market.

However, certain factors such as the high cost of ureteroscope devices and the postoperative complications like blood loss during internal bleeding may be certain limiting factors of the Urolithiasis Management Devices market growth.

The outbreak of the COVID-19 pandemic caused a significant decrease in emergency department visits. Moreover, there was a delay in outpatient clinic appointments which pushed the need towards virtual or telephone clinics. Due to a lack of in-hospital beds, anesthesia or procedural slots, and healthcare professionals, these changes created a significant backlog in the treatment, thereby creating a negative impact on the Global Urolithiasis Management Devices market.

Urolithiasis Management Devices Market Segment Analysis:

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Treatment segment of the Urolithiasis Management Devices market, the Extracorporeal Shock Wave Lithotripters (ESWL) is estimated to hold a higher share in the Urolithiasis Management Devices market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The large market share of this product segment can be attributed to the growing patient adoption of these devices and quick treatment. The main benefit of ESWL is that the treatment is totally non-invasive, as it does not involve any skin incisions or the use of any invasive surgical instruments to treat the stone. Instead, shock waves are utilized to shatter the stone into tiny fragments that flow through the ureter and out of the bladder.

It also has other advantages such as reduced pain, quick recovery time, and shorter hospital stays. This treatment method is chosen by a majority of the patient and physician population.

ESWL is suited for small stones as well as certain stones present in the upper portion of the ureter. Moreover, multiple stones can also be treated with ESWL. Therefore, it is expected that with such advantages offered by the Extracorporeal Shock Wave Lithotripsy Devices this technology is expected to increase its penetration in coming years, thus this will drive the segment to grow during the forecast period, which will have a positive impact on the overall Global Urolithiasis Management Devices Market growth.

Furthermore, Extracorporeal Shock Wave Lithotripsy Devices are gaining commercial acceptability, which also improves market penetration. All these advantages of these devices make physicians more inclined to use Extracorporeal Shock Wave Lithotripsy Devices.

Hence, all the above-mentioned factors are expected to drive the segment growth of the Urolithiasis Management Devices market.

North America is expected to dominate the overall Urolithiasis Management Devices Market:

Among all the regions, North America is expected to account for the largest share in the Global Urolithiasis Management Devices market. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals are expected to aid in the growth of the North America Urolithiasis Management Devices Market.

As per the Canadian Urological Association guidelines 2022, globally, the prevalence of urolithiasis is steadily increasing, and though some regional variability exists, contemporary estimates report up to 10-12% of men and 7-8% of women now suffer from nephrolithiasis.

Moreover, according to the US Department of Health and Human Services 2022, end-stage renal disease (ESRD) is a significant public health problem in the United States and a major source of suffering and poor quality of life for those afflicted.

Another factor responsible for the growth of the Urolithiasis Management Devices market is the launch of new products in the region. For instance, in 2019, Dornier Medtech launched and announced the immediate availability of its new AXIS single-use digital flexible ureteroscope in the US.

In 2019, Shockwave Medical Inc. received breakthrough device designation for its intravascular lithotripsy (IVL) therapy, used for lithotripsy and was long used to eliminate kidney stones.

Thus, these factors are projected to contribute to the Urolithiasis Management Devices market during the forecasted period.

The rising adoption of Urolithiasis Management Devices in the country would result in the rising demand for treatments that make use of Urolithiasis Management Devices, which in turn would provide a conducive growth environment for the United States Urolithiasis Management Devices market as well as the North American region. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Urolithiasis Management Devices market during the forecast period.

Urolithiasis Management Devices Market Key Players:

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

Recent Developmental Activities in the Urolithiasis Management Devices Market:

In March 2022, Boston Scientific acquired Lumenis in a USD 1.07 billion deal. With this acquisition, Boston Scientific has strengthened its product portfolio for Lithotripsy devices. This will further add to the growth of the Global Urolithiasis Management Devices market.

In March 2022, Dornier MedTech GmbH became the world's first integrated urology company to be certified by the European Union's Medical Device Regulation (MDR). Dornier achieved the certification for its Class IIb products: Dornier Delta® III, one of the most powerful lithotripters that utilize Dornier's Extracorporeal Shock Wave Lithotripsy (ESWL) technology; and the Dornier UIMS(TM), a state-of-the-art information management software providing enhanced imaging and efficiency to support clinicians in treating kidney stones.

In August 2020, Olympus Winter & Ibe GmbH received the US FDA approval for OES Elite Ureteroscopes and Accessories under regulatory class II for endoscopic observation and therapy in the ureters, urethra, and urinary bladder.

Key Takeaways from the Urolithiasis Management Devices Market Report Study

  • Market size analysis for current Urolithiasis Management Devices market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Urolithiasis Management Devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global Urolithiasis Management Devices market.
  • Various opportunities available for the other competitor in the Urolithiasis Management Devices market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current Urolithiasis Management Devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Urolithiasis Management Devices market growth in the coming future?

Target Audience who can be benefited from this Urolithiasis Management Devices Market Report Study

  • Urolithiasis Management Devices products providers
  • Research organizations and consulting companies
  • Urolithiasis Management Devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Urolithiasis Management Devices
  • Various End-users who want to know more about the Urolithiasis Management Devices market and latest technological developments in the Urolithiasis Management Devices market.

Frequently Asked Questions for the Urolithiasis Management Devices Market:

1. What is Urolithiasis Management Devices?

Urolithiasis Management Devices are devices used to manage Kidney stones (also called renal calculi, nephrolithiasis, or urolithiasis) that form inside kidneys.

2. What is the market for Global Urolithiasis Management Devices?

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030.

3. What are the drivers for the Global Urolithiasis Management Devices Market?

The Urolithiasis Management Devices market is witnessing a positive market growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market.

4. Who are the key players operating in the Global Urolithiasis Management Devices Market?

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

5. Which region has the highest share in Urolithiasis Management Devices Market?

North America is expected to hold the highest share in the revenue in the Urolithiasis Management Devices market during the forecast period. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals, are expected to aid in the growth of the North America Urolithiasis Management Devices Market in this region.

Table of Contents

1.Urolithiasis Management Devices Market Report Introduction

2.Urolithiasis Management Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Urolithiasis Management Devices Market Key Factors Analysis

  • 4.1. Urolithiasis Management Devices Market Drivers
    • 4.1.1. The Rising Prevalence of Urolithiasis or Nephrolithiasis
    • 4.1.2. Sedentary Lifestyle as a Risk Factor for the Development of Kidney Stones
    • 4.1.3. Innovation in Product Design
    • 4.1.4. Increased Risk of End-Stage Renal Failure
    • 4.1.5. Growing Geriatric Population
  • 4.2. Urolithiasis Management Devices Market Restraints and Challenges
    • 4.2.1. The High Cost of Ureteroscope Devices
    • 4.2.2. The Postoperative Complications
  • 4.3. Urolithiasis Management Devices Market Opportunities
    • 4.3.1. Need For Advanced Devices
    • 4.3.2. Growing Opportunities in Single-Use Ureteroscope

5. Urolithiasis Management Devices Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Urolithiasis Management Devices Market

7. Urolithiasis Management Devices Market Layout

  • 7.1. By Type
    • 7.1.1. Diagnostics
      • 7.1.1.1. X-ray
      • 7.1.1.2. Computed Tomography
      • 7.1.1.3. Ultrasound
      • 7.1.1.4. Others
    • 7.1.2. Treatment
      • 7.1.2.1. Shock Wave Lithotripters
      • 7.1.2.1.1. Intracorporeal
      • 7.1.2.1.2. Extracorporeal
      • 7.1.2.2. Ureteroscopes
      • 7.1.2.2.1. Semi-Rigid
      • 7.1.2.2.2. Flexible
      • 7.1.2.3. Stone Retrieval Devices
      • 7.1.2.4. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States
      • 7.3.1.2. Canada
      • 7.3.1.3. Mexico
    • 7.3.2. Europe
      • 7.3.2.1. France
      • 7.3.2.2. Germany
      • 7.3.2.3. United Kingdom
      • 7.3.2.4. Italy
      • 7.3.2.5. Spain
      • 7.3.2.6. Russia
      • 7.3.2.7. Rest of Europe
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China
      • 7.3.3.2. Japan
      • 7.3.3.3. India
      • 7.3.3.4. Australia
      • 7.3.3.5. South Korea
      • 7.3.3.6. Rest of Asia Pacific
    • 7.3.4. Rest of the World (RoW)

8. Urolithiasis Management Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Urolithiasis Management Devices Market Company and Product Profiles

  • 9.1. Boston Scientific Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. EMS Urology
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Advin Health Care
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Inceler Medikal Co. Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Walz Elektronik GmbH
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. DirexGroup
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Medispec Ltd.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Richard Wolf GmbH
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. STORZ MEDICAL AG
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Olympus
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. General Electric Company (GE Healthcare)
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. ESAOTE SPA
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. BK Medical Holding Company, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Hitachi Medical Systems
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Laborie
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. DRAMINSKI S. A.
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. ACE Medical Devices Pvt. Ltd.
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Siemens Healthcare Private Limited
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Vimex Sp. z o.o.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Table 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Table 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Table 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Table 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Table 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Table 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Table 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Table 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Table 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Table 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Table 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Table 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Table 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Table 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Table 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Table 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Table 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Table 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Table 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Table 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Table 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Table 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Table 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Table 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Table 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Table 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Table 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Figure 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Figure 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Figure 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Figure 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Figure 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Figure 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Figure 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Figure 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Figure 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Figure 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Figure 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Figure 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Figure 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Figure 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Figure 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Figure 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Figure 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Figure 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Figure 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Figure 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Figure 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Figure 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Figure 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Figure 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Figure 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Figure 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Figure 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis